2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2023-06-17
±³À°ÀÏÀÚ : 2023-06-17
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ / ÄÁÆÛ·±½º·ë 1~3
±³À°ÁÖÁ¦ : "2023³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ"
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ
´ã´çÀÚ : ÃÖÀº¿µ
¿¬¶ôó : 070-8873-6030
À̸ÞÀÏ : k-iscp@naver.com
±³À°Á¾·ù : ³»°ú, ½Å°æ¿Ü°ú
Âü¼®¿¹»óÀÎ : 160¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:00~09:20 Optimal medical treatment after ablation or electrical cardioversion of atrial fibrillation ÃÖÀ±¿µ (°í·ÁÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:20~09:40 Second-line medication for ischemic ventricular tachyarrhythmia ±èÈÁß(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 09:40~10:00 Medical treatment for inherited primary arrhythmia syndrome ±è¹Î (ÃæºÏÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 10:00~10:20 Decision making for the recurred AF after ablation Á¤Çü±â (¿ø±¤ÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 06¿ù 17ÀÏ AIȦ 10:20~10:30 Åä·Ð ()
ÈÞ½Ä 06¿ù 17ÀÏ 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 10:50~11:10 Aspirin vs. Clopidogrel for chronic maintenance monotherapy after PCI: HOST-EXAM extended study ¹Ú°æ¿ì(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:10~11:30 CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk Á¶»óÈ£(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:30~11:50 PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction ÃÖÀÍÁØ(°¡Å縯ÀÇ´ë ½ÉÀåÇ÷°ü³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 11:50~12:10 LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients With Coronary Artery Disease ¼Û¿µºó(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 06¿ù 17ÀÏ AIȦ 12:10~12:20 Åä·Ð ()
±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 10:50~11:10 How to control hypertriglyceridemia and low HDL? ¿À±Ôö(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:10~11:30 Statin + Ezetimibe vs high dose statin ±è»óÇö(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:30~11:50 Co-enzyme Q10 and statin ÀÌÇØ¿µ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:50~12:10 ¼øȯ±â ¿Ü·¡È¯ÀÚ¿¡¼ ÀÚ°¡Åõ¿©ÁÖ»ç ÇöȲ ¹× ±³À° ¹éÁö¿ø(ºÐ´ç¼¿ï´ëº´¿ø ¾àÁ¦ºÎ)
Åä·Ð 06¿ù 17ÀÏ ÄÁÆÛ·±½º·ë 1~3 12:10~12:20 Åä·Ð ()
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 12:20~12:40 GLP1 agonist in obesity and diabetes control ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú)
½Ä»ç 06¿ù 17ÀÏ 12:40~13:30 ½Ä»ç ()
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 13:30~13:50 What ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 13:50~14:10 New pipelines for hypertension ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 14:10~14:30 Comparison of calcium channel blockers ÀÌÀº¹Ì(¿ø±¤ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 14:30~14:50 Comparison of thiazide diuretics ±è´ëÈñ(¿ï»êÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 06¿ù 17ÀÏ AIȦ 14:50~15:00 Åä·Ð ()
ÈÞ½Ä 06¿ù 17ÀÏ 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 15:20~15:40 Myocardial function recovery at HFrEF ¹Ú¹ÎÁ¤(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 15:40~16:00 Severe hypercholesterolemia in very thin young woman ¹ÚÀçÀÏ(¼¿ï´ëÇб³º´¿ø ³»°ú )
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:00~16:20 Pharmacological treatment of AF À̼öÇö(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:20~16:40 Optimal treatment of resistant hypertension : Difficult control ±èÇöÁø(ÇѾçÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ AIȦ 16:40~16:50 Defer Revascularization of Vulnerable Plaque in NSTEMI ±èÈ£¿¬ (¿ï»êÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 06¿ù 17ÀÏ AIȦ 16:50~17:00 Åä·Ð ()